LON:ABZA - Abzena Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
GBX 9.75 -0.25 (-2.50 %)
(As of 06/22/2018 04:00 PM ET)
Previous CloseGBX 10
Today's RangeGBX 9.50 - GBX 9.98
52-Week RangeGBX 24.50 - GBX 53
Volume399,748 shs
Average Volume26,706 shs
Market Capitalization£50.91 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Abzena logoAbzena plc engages in the provision of services and technologies for the development and commercialization of biopharmaceutical products in North America, Europe, the United Kingdom, and internationally. It provides antibody drug conjugate linker, antibody humanization, and protein deimmunisation technologies and solutions, which include phage display, Hybridoma sequencing, and developability assessment solutions for the discovery, isolation, development, and selection of antibodies; immunogenicity assessment and custom assays, as well as Cytokine Screen, an in vitro assay to evaluate the risk of biopharmaceutical products causing cytokine release syndrome prior to its test in clinical trials; antibody and protein engineering solutions, which cover Ig class and isotype switching, antibody reformatting and humanization, protein deimmunisation, affinity maturation, antibody and protein production, and bioassays and bioanalytics; and antibody drug conjugates, such as cysteine and lysine conjugation solutions, as well as ThioBridge, a disulfide rebridging linker. The company also provides solutions in the area of bioassays, which cover drug-conjugate and payload characterization, binding and competition assays, cell health assays, functional assays, Fc binding and function assays, and bespoke assay development; bioanalytics that cover candidate selection, biosimilarity, protein and peptide identification, ADC characterization, and analytical method development; mammalian manufacturing; peptide synthesis, modifications, and analytics; bioconjugate and antibody drug conjugate manufacturing; and chemical synthesis. It serves biopharmaceutical research and development industry. Abzena plc has a co-development agreement with Enleofen Bio Pte Ltd. to develop antibody therapeutics for the treatment of fibrotic human diseases. The company was incorporated in 2014 and is headquartered in Cambridge, the United Kingdom.

Receive ABZA News and Ratings via Email

Sign-up to receive the latest news and ratings for ABZA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolLON:ABZA
CUSIPN/A
Phone+44-1223-903498

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-83.31%
Return on Equity-36.99%
Return on Assets-30.72%

Miscellaneous

EmployeesN/A
Outstanding Shares213,820,000

Abzena (LON:ABZA) Frequently Asked Questions

What is Abzena's stock symbol?

Abzena trades on the London Stock Exchange (LON) under the ticker symbol "ABZA."

What price target have analysts set for ABZA?

3 Wall Street analysts have issued 12-month price objectives for Abzena's stock. Their forecasts range from GBX 40 to GBX 70. On average, they expect Abzena's share price to reach GBX 57.33 in the next twelve months. View Analyst Ratings for Abzena.

Who are some of Abzena's key competitors?

Who are Abzena's key executives?

Abzena's management team includes the folowing people:
  • Dr. William John Edward Burt DPhil, Chief Exec. Officer & Exec. Director (Age 50)
  • Mr. Julian Mathew Smith, CFO, Company Sec. & Exec. Director (Age 53)
  • Prof. Sunil Shaunak M.D., Ph.D., Co-Founder and Chairman of the Scientific Advisory Board
  • Dr. Antony Godwin Ph.D., Co-Founder
  • Prof. Steve Brocchini Ph.D., Co-Founder

Has Abzena been receiving favorable news coverage?

Press coverage about ABZA stock has trended somewhat positive on Friday, according to Accern. The research group identifies positive and negative press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Abzena earned a daily sentiment score of 0.11 on Accern's scale. They also assigned media headlines about the company an impact score of 48.19 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next several days.

How do I buy shares of Abzena?

Shares of ABZA and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Abzena's stock price today?

One share of ABZA stock can currently be purchased for approximately GBX 9.75.

How big of a company is Abzena?

Abzena has a market capitalization of £50.91 million.

How can I contact Abzena?

Abzena's mailing address is Babraham Hall, Babraham Research, CAMBRIDGE, CB22 3AT, United Kingdom. The company can be reached via phone at +44-1223-903498.


MarketBeat Community Rating for Abzena (ABZA)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  147 (Vote Outperform)
Underperform Votes:  93 (Vote Underperform)
Total Votes:  240
MarketBeat's community ratings are surveys of what our community members think about Abzena and other stocks. Vote "Outperform" if you believe ABZA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABZA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.